NHS Logo
Bedfordshire and Luton Joint Formulary
Bedfordshire Hospitals NHS Foundation Trust
Bedfordshire, Luton and Milton Keynes ICB
Formulary Chapter: 8 - Malignant disease and immunosuppression 
Notes:

Any drug not listed on the Formulary should be considered Non-Formulary - Not recommended for prescribing
08.01.05 Other antineoplastic drugs

Abemaciclib (Verzenios®)
(Tablets)

RED
Restricted Drug Restricted

FOR ALL PRESCRIBING – Blueteq or High cost drug form required – see link from Formulary homepage.

Approved for use in accordance with the follwing NICE TAs:

BNF BNFc SPC
NICE TA563 Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer NICE TA725 Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy NICE TA810 Abemaciclib with endocrine therapy for adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence

Alpelisib (Piqray®)
(50mg, 150mg and 200mg film-coated tablets)

RED
Restricted Drug Restricted

FOR ALL PRESCRIBING – Blueteq or High cost drug form required – see link from Formulary homepage.

Approved for use in accordance with the following NICE TA(s):

BNF BNFc SPC
NICE TA816: Alpelisib with fulvestrant for treating hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer

Atezolizumab 840mg & 1200mg (Tecentriq®)
(Intravenous infusion)

RED
Restricted Drug Restricted

Funding approval required.

Funding approval required for use in line with the other NICE TAs below:

BNF BNFc SPC
NICE TA492: Atezolizumab for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable NICE TA520: Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy NICE TA525: Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy NICE TA584 Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer NICE TA638: Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer NICE TA639: Atezolizumab with nab-paclitaxel for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer NICE TA666: Atezolizumab with bevacizumab for treating advanced or unresectable hepatocellular carcinoma NICE TA705: Atezolizumab monotherapy for untreated advanced non-small-cell lung cancer NICE TA739: Atezolizumab for untreated PD-L1-positive advanced urothelial cancer when cisplatin is unsuitable NICE TA823: Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer NICE TA1047: Atezolizumab for untreated advanced or recurrent non-small-cell lung cancer when platinum-doublet chemotherapy is unsuitable (TERMINATED APPRAISAL) NICE TA1071: Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer

Avelumab 20mg/mL (Bavencio®)
(Concentrate for infusion)

RED
Restricted Drug Restricted

FOR ALL PRESCRIBING - Blueteq or High cost drug form requested - see link on Formulary Homepage.

 To be used in accordance with criteria in the following  NICE TAs:-

NB - mixture of routine Commissioning and Cancer Drugs Fund

BNF BNFc SPC
NICE TA517: Avelumab for treating metastatic Merkel cell carcinoma NICE TA645 Avelumab with axitinib for untreated advanced renal cell carcinoma NICE TA691 Avelumab for untreated metastatic Merkel cell carcinoma NICE TA788 Avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapy

Axicabtagene ciloleucel (Yescarta®)
(Infusion)

RED
Restricted Drug Restricted

FOR ALL PRESCRIBING - Blueteq or High cost drug form requested - see link on Formulary Homepage.

 To be used in accordance with criteria in the following  NICE TAs:

BNF BNFc SPC
NICE TA559: Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies (replaced by TA872 - see below) NICE TA872: Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies NICE TA894: Axicabtagene ciloleucel for treating relapsed or refractory follicular lymphoma (not recommended) NICE TA895: Axicabtagene ciloleucel for treating relapsed or refractory diffuse large B-cell lymphoma after first-line chemoimmunotherapy

Axitinib (Inlyta®)

RED
Restricted Drug Restricted

FOR ALL PRESCRIBING – Blueteq or High cost drug form required – see link from Formulary homepage.

Restricted to prescribing in accordance with the following NICE TAs (NB NICE TA645 is funded via the Cancer Drugs Fund):-

BNF BNFc SPC
NICE TA 645 Avelumab with axitinib for untreated advanced renal cell carcinoma NICE TA333: Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment

Belzutifan (Welireg®)
(40 mg film-coated tablets)

RED
Restricted Drug Restricted

FOR ALL PRESCRIBING – Blueteq or High cost drug form required – see link from Formulary homepage.

Approved for use in accordance with the following NICE TA(s):

BNF BNFc SPC
NICE TA1011: Belzutifan for treating tumours associated with von Hippel-Lindau disease Welireg ® (belzutifan) Patient alert cards to minimise the risk of hypoxia related adverse reactions

Binimetinib 15mg (Mektovi®)
(Tablets)

RED
Restricted Drug Restricted

FOR ALL PRESCRIBING – Blueteq or High cost drug form required – see link from Formulary homepage.

Approved for use with encorafenib in accordance with the NICE TA below.

BNF BNFc SPC
NICE TA562: Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma

Bosutinib (Bosulif®)

RED
Restricted Drug Restricted
FOR ALL PRESCRIBING – Blueteq or High cost drug form required – see link from Formulary homepage.
Restricted - prescribing by Oncologists according to NICE TA401.
BNF BNFc SPC
NICE TA401: Bosutinib for previously treated CML.

Brentuxumab (Adcetris®)

RED
Restricted Drug Restricted

FOR ALL PRESCRIBING – Blueteq or High cost drug form required – see link from Formulary homepage.
Restricted - prescribing by Oncologists according to NICE TA524.

BNF BNFc SPC
NICE TA524: Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma

Brexucabtagene autoleucel (Tecartus®)
(Dispersion for infusion)

RED
Restricted Drug Restricted

FOR ALL PRESCRIBING – Blueteq or High cost drug form required – see link from Formulary homepage.

Approved in line with the following NICE TA(s) only:

BNF BNFc SPC
NICE TA893: Brexucabtagene autoleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 26 years and over

Brigatinib (Alunbrig®)
(Tablets)

RED
Restricted Drug Restricted

FOR ALL PRESCRIBING – Blueteq or High cost drug form required – see link from Formulary homepage.

Approved in accordance with the NICE TA(s) below.

BNF BNFc SPC
NICE TA 670 Brigatinib for ALK-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitor NICE TA571: Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib

Capivasertib (Truqap®)
(160mg, 200mg film-coated tablets)

RED
Restricted Drug Restricted

FOR ALL PRESCRIBING – Blueteq or High cost drug form required – see link from Formulary homepage.

Approved for use in accordance with the following NICE TA(s):

BNF BNFc SPC
NICE TA1063: Capivasertib with fulvestrant for treating hormone receptor-positive HER2-negative advanced breast cancer after endocrine treatment

Carfilzomib 10mg. 30mg, 60mg (Kyprolis®)
(Intravenous infusion)

RED
Restricted Drug Restricted

FOR ALL PRESCRIBING – Blueteq or High cost drug form required – see link from Formulary homepage.

Approved in line with the following NICE TAs only:-

BNF BNFc SPC
MHRA Drug Safety Update (November 2019) - Carfilzomib (Kyprolis¥): risk of reactivation of hepatitis B virus NICE TA 657 Carfilzomib for previously treated multiple myeloma NICE TA 695 Carfilzomib with dexamethasone and lenalidomide for previously treated multiple myeloma

Cemiplimab (Libtayo®)
(350 mg concentrate for solution for infusion)

RED
Restricted Drug Restricted

FOR ALL PRESCRIBING - Blueteq or High Cost Drug Form required - see link from Formulary homepage.

Restricted to prescribing in accordance with the following NICE TAs:

BNF BNFc SPC BlueTeq
NICE TA592 Cemiplimab for treating metastatic or locally advanced cutaneous squamous cell carcinoma NICE TA802 Cemiplimab for treating advanced cutaneous squamous cell carcinoma

Ceritinib (Zykadia)

RED
Restricted Drug Restricted

FOR ALL PRESCRIBING – Blueteq or High cost drug form required – see link from Formulary homepage.
Restricted - for use by Oncologists in line with NICE TA395 and TA500.

BNF BNFc SPC BlueTeq
NICE TA395: Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer NICE TA500: Ceritinib for untreated ALK-positive non-small-cell lung cancer

Crizotinib (Xalkori®)

RED
Restricted Drug Restricted

Commissioned by Not NHSNHS England.
FOR ALL PRESCRIBING – Blueteq or High cost drug form required – see link from Formulary homepage.

To be prescribed by specialists in line with NICE TA422 and TA529.

BNF BNFc SPC
NICE TA422: Crizotinib for previously treated anaplastic lymphoma kinase- positive advanced non-small-cell lung cancer NICE TA529: Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer (replaced by TA1021) NICE TA1021: Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer

Dabrafenib (Tafinlar®)

RED
Formulary

FOR ALL PRESCRIBING – Blueteq or High cost drug form required – see link from Formulary homepage.

Restricted to prescribing in accordance with NICE TAs below.

BNF BNFc SPC
NICE TA321: Dabrafenib for treating unresectable or metastatic BRAF V600 mutation‑positive melanoma NICE TA396: Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma NICE TA544: Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma NICE TA898: Dabrafenib plus trametinib for treating BRAF V600 mutation-positive advanced non-small-cell lung cancer NICE TA977: Dabrafenib with trametinib for treating BRAF V600E mutation-positive glioma in children and young people aged 1 year and over

Dacomitinib (Vizimpro®)
(15mg, 30mg and 45mg film-coated tablets)

RED
Restricted Drug Restricted

FOR ALL PRESCRIBING - Blueteq or high cost drug form required - see link from formulary homepage.

To be prescribed by specialists in line with the following NICE TA(s):-

BNF BNFc SPC BlueTeq
TA595 Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer

Daratumumab 20mg/mL (Darzalex®)
(Concentrate for infusion)

RED
Restricted Drug Restricted

FOR ALL PRESCRIBING - Blueteq or high cost drug form required - see link from formulary homepage.

For use in accordance with the following NICE TAs (TA 510 and TA 573 funded via the Cancer Drugs fund):-

BNF BNFc SPC
NICE TA510: Daratumumab monotherapy for treating relapsed and refractory multiple myeloma NICE TA573 Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma (replaced by NICE TA897) NICE TA763 Daratumumab in combination for untreated multiple myeloma when a stem cell transplant is suitable NICE TA783: Daratumumab monotherapy for treating relapsed and refractory multiple myeloma NICE TA897: Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma NICE TA917: Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitable NICE TA959: Daratumumab in combination for treating newly diagnosed systemic amyloid light-chain amyloidosis

Dasatinib (Sprycel®)

RED
Restricted Drug Restricted
Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma
To be prescribed by specialists in line with NICE TA425 and TA426.
BNF BNFc SPC
NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia

Dostarlimab (Jemperli®)
(500mg/10ml concentrate for solution for infusion vials)

RED
Restricted Drug Restricted

FOR ALL PRESCRIBING - Blueteq or High cost drug form requested - see link on Formulary Homepage.

To be used in accordance with criteria in the following NICE TAs (via the Cancer Drugs Fund for TA779):

BNF BNFc SPC
NICE TA779: Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency NICE TA1064: Dostarlimab with platinum-based chemotherapy for treating primary advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency NICE TA1117: Dostarlimab with platinum-containing chemotherapy for treating primary advanced or recurrent endometrial cancer with microsatellite stability or mismatch repair proficiency

Durvalumab (Imfinzi®)
(50 mg/ml concentrate solution for infusion)

RED
Restricted Drug Restricted

FOR ALL PRESCRIBING - Blueteq or High Cost Drug Form required - see link from Formulary Home Page.

For use in accordance with the following NICE TA(s):

BNF BNFc SPC
NICE TA578: Durvalumab for treating locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation NICE TA798: Durvalumab for maintenance treatment of unresectable non-small-cell lung cancer after platinum-based chemoradiation NICE TA944: Durvalumab with gemcitabine and cisplatin for treating unresectable or advanced biliary tract cancer NICE TA1030: Durvalumab with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer NICE TA1041: Durvalumab with etoposide and either carboplatin or cisplatin for untreated extensive-stage small-cell lung cancer NICE TA1090: Durvalumab with tremelimumab for untreated advanced or unresectable hepatocellular carcinoma NICE TA1099: Durvalumab for treating limited-stage small-cell lung cancer after platinum-based chemoradiotherapy

Elranatamab (Elrexfio®)
(40 mg/mL solution for injection)

RED
Restricted Drug Restricted

FOR ALL PRESCRIBING – Blueteq or High cost drug form required – see link from Formulary homepage.

Approved for use in accordance with the follwing NICE TA(s):

BNF BNFc SPC
NICE TA1023: Elranatamab for treating relapsed and refractory multiple myeloma after 3 or more treatments

Encorafenib 50mg, 75mg (Braftovi ®)
(Capsules)

RED
Restricted Drug Restricted

FOR ALL PRESCRIBING – Blueteq or High cost drug form required – see link from Formulary homepage.

Approved for use with binimetinib in accordance with NICE TA 562 - see link below

Approved for use with cetuximab in accordance with NICE TA 668 - see link below

BNF BNFc SPC
NICE TA562: Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma NICE TA 668 Encorafenib plus cetuximab for previously treated BRAF V600E mutation-positive metastatic colorectal cancer

Enfortumab vedotin (Padcev®)
(20mg, 30mg powder for concentrate for solution for infusion)

RED
Restricted Drug Restricted

FOR ALL PRESCRIBING – Blueteq or High cost drug form required – see link from Formulary homepage.

Approved for use in accordance with the following NICE TAs:

 

Entry added: September 2025

BNF BNFc SPC
NICE TA1097: Enfortumab vedotin with pembrolizumab for untreated unresectable or metastatic urothelial cancer when platinum-based chemotherapy is suitable

Entrectinib (Rozlytrek®)
(100 mg and 200 mg hard capsules)

RED
Restricted Drug Restricted

FOR ALL PRESCRIBING - Blueteq or High cost drug form required - see link from Formulary homepage

For use in accordance with the following NICE TAs:-

BNF BNFc SPC BlueTeq
NICE TA 643 Entrectinib for treating ROS1-positive advanced non-small-cell lung cancer NICE TA 644 Entrectinib for treating NTRK fusion-positive solid tumours

Epcoritamab (Tepkinly®)
(4 mg/0.8 ml concentrate for solution for injection; 48 mg solution for injection)

RED
Restricted Drug Restricted

FOR ALL PRESCRIBING – Blueteq or High cost drug form required – see link from Formulary homepage.

For use in accordance with the following NICE TA(s):

BNF BNFc SPC
NICE TA954: Epcoritamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments

Eribulin (Halaven®)

RED
Restricted Drug Restricted

FOR ALL PRESCRIBING – Blueteq or High cost drug form required – see link from Formulary homepage.
Commissioned by Not NHSNHS England.

To be prescribed by specialists in line with NICE TA423 & TA515.

BNF BNFc SPC
NICE TA423: Eribulin for treating locally advanced or metastatic breast cancer NICE TA515: Eribulin for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimen

Fedratinib (Inrebic®)
(100 mg hard capsules)

RED
Restricted Drug Restricted

FOR ALL PRESCRIBING - Blueteq or High cost drug form required - see link from Formulary Homepage.

For use in accordance with the following NICE TA(s):

BNF BNFc SPC BlueTeq
NICE TA756 Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis (replaced by TA1018) NICE TA1018: Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis

Glofitamab (Columvi®)
(Intravenous infusion)

RED
Restricted Drug Restricted

FOR ALL PRESCRIBING – Blueteq or High cost drug form required – see link from Formulary homepage.

Approved for use in accordance with the follwing NICE TA(s):

BNF BNFc SPC
NICE TA927: Glofitamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments NICE TA1113: Glofitamab with gemcitabine and oxaliplatin for treating relapsed or refractory diffuse large B-cell lymphoma

Ibrutinib 140mg (Imbruvica®)
(Capsules)

RED
Restricted Drug Restricted

Blueteq or High cost drug form required – see link from Formulary homepage.

To be prescribed by Haematologists in line with NICE TAs below.

BNF BNFc SPC
MHRA DSU Aug 17: Ibrutinib (Imbruvica▼): reports of ventricular tachyarrhythmia; risk of hepatitis B reactivation and of opportunistic infections NICE TA429: Ibrutinib for previously treated CLL NICE TA491: Ibrutinib for treating Waldenstrom’s macroglobulinaemia NICE TA502: Ibrutinib for treating relapsed or refractory mantle cell lymphoma NICE TA891: Ibrutinib with venetoclax for untreated chronic lymphocytic leukaemia

Idelalisib (Zydelig®)

RED
Restricted Drug Restricted
FOR ALL PRESCRIBING – Blueteq or High cost drug form required – see link from Formulary homepage.
100mg Tablets

Approved in accordance with NICE TA359 for the treatment of chronic lymphocytic leukaemia

Restricted - must only be prescribed by staff with specialist training in Oncology or Haematology
BNF BNFc SPC
MHRA Drug Safety Update (May 2016) - Idelalisib (Zydelig▼): interim measures following signal of serious infection and deaths related to infection found in clinical trials NICE TA359: Idelalisib for treating chronic lymphocytic leukaemia

Ivosidenib (Tibsovo®)
(250 mg film-coated tablets)

RED
Restricted Drug Restricted

FOR ALL PRESCRIBING – Blueteq or High cost drug form required – see link from Formulary homepage.

Approved for use in accordance with the follwing NICE TA(s):

BNF BNFc SPC
NICE TA948: Ivosidenib for treating advanced cholangiocarcinoma with an IDH1 R132 mutation after 1 or more systemic treatments NICE TA979: Ivosidenib with azacitidine for untreated acute myeloid leukaemia with an IDH1 R132 mutation

Ixazomib (Ninlaro®)
(2.3mg, 3mg, 4mg capsules)

RED
Restricted Drug Restricted

FOR ALL PRESCRIBING – Blueteq or High cost drug form required – see link from Formulary homepage.

Prescribing by specialist in line with the NICE TA(s) below:

BNF BNFc SPC
NICE TA505: Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (superseded by TA870) NICE TA870: Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma

Lenvatinib (Lenvima®, Kisplyx®)
(4mg, 10mg capsules)

RED
Restricted Drug Restricted

FOR ALL PRESCRIBING – Blueteq or High cost drug form required – see link from Formulary homepage.

Prescribing by specialist in line with the NICE TA's below.

BNF BNFc SPC
NICE TA498: Lenvatinib with everolimus for previously treated advanced renal cell carcinoma NICE TA535: Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine NICE TA551: Lenvatinib for untreated advanced hepatocellular carcinoma NICE TA858: Lenvatinib with pembrolizumab for untreated advanced renal cell carcinoma NICE TA904: Pembrolizumab with lenvatinib for previously treated advanced or recurrent endometrial cancer

Loncastuximab tesirine (Zynlonta®)
(10mg powder for concentrate for solution for infusion)

RED
Restricted Drug Restricted

FOR ALL PRESCRIBING – Blueteq or High cost drug form required – see link from Formulary homepage.

Approved for use in accordance with the following NICE TA(s):

BNF BNFc SPC
NICE TA947: Loncastuximab tesirine for treating relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma after 2 or more systemic treatments

Lorlatinib (Lorviqua® )
(25mg and 100mg film coated tablets)

RED
Restricted Drug Restricted

FOR ALL PRESCRIBING - Blueteq or High cost drug form required - see link from Formulary homepage.

Approved in accordance with the following NICE TA(s):

BNF BNFc SPC
NICE TA628: Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer NICE TA1103: Lorlatinib for ALK-positive advanced non-small-cell lung cancer that has not been treated with an ALK inhibitor

Midostaurin 25mg (Rydapt®)
(Capsules)

RED
Restricted Drug Restricted

FOR ALL PRESCRIBING – Blueteq or High cost drug form required – see link from Formulary homepage.

Prescribing by specialist in line with the following NICE TAs

BNF BNFc SPC
NICE TA 728 Midostaurin for treating advanced systemic mastocytosis NICE TA523: Midostaurin for untreated acute myeloid leukaemia

Neratinib (Nerlynx®)
(40mg film-coated tablets)

RED
Restricted Drug Restricted

FOR ALL PRESCRIBING - Blueteq or high cost drug form required - see link from Formulary Home Page.

Restricted for use in accordance with the following NICE TA(s):

BNF BNFc SPC
NICE TA612 Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab

Niraparib 100mg (Zejula®)
(Capsules)

RED
Restricted Drug Restricted

Funded by Cancer Drug Fund. Prescribing by specialist in line with NICE TA528 and NICE TA 673

BNF BNFc SPC
MHRA Drug Safety Update (October 2020): Niraparib (Zejula▼): reports of severe hypertension and posterior reversible encephalopathy syndrome (PRES), particularly in early treatment NICE TA528: Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer NICE TA673: Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy NICE TA784: Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer NICE TA1032: Niraparib with abiraterone acetate and prednisone for untreated hormone-relapsed metastatic prostate cancer (TERMINATED APPRAISAL)

Olaparib (Lynparza®)

RED
Formulary

FOR ALL PRESCRIBING – Blueteq or High cost drug form required – see link from Formulary homepage.

50mg hard capsules

100mg and 150mg film-coated tablets

Approved in accordance with the following NICE TA(s). NB NICE TA 598 and NICE TA 693 indications  and one indication in TA 620 are funded via the Cancer Drugs Fund.

BNF BNFc SPC
NICE TA381: Olaparib for maintenance treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer NICE TA598: Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy NICE TA620: Olaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer NICE TA693: Olaparib plus bevacizumab for maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer NICE TA831: Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer (NOT recommended, replaced by TA887) NICE TA886: Olaparib for adjuvant treatment of BRCA mutation-positive HER2-negative high-risk early breast cancer after chemotherapy NICE TA887: Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer NICE TA908: Olaparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube or peritoneal cancer after 2 or more courses of platinum-based chemotherapy NICE TA946: Olaparib with bevacizumab for maintenance treatment of advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer NICE TA951: Olaparib with abiraterone for untreated hormone-relapsed metastatic prostate cancer NICE TA1040: Olaparib for treating BRCA mutation-positive HER2-negative advanced breast cancer after chemotherapy

Panitumumab (Vectibix®)

RED
Formulary

FOR ALL PRESCRIBING – Blueteq or High cost drug form required – see link from Formulary homepage.

20 mg/mL concentrate for solution for infusion

Approved in accordance with NICE TA 439 

BNF BNFc SPC
NICE TA439: Cetuximab and panitumumab for previously untreated metastatic colorectal cancer

Panobinostat (Farydak®)
(Capsules)

RED
Restricted Drug Restricted

FOR ALL PRESCRIBING – Blueteq or High cost drug form required – see link from Formulary homepage.


Approved in accordance with NICE TA380.

BNF BNFc SPC
NICE TA380: Panobinostat for treating multiple myeloma after at least 2 previous treatments

Pembrolizumab (Keytruda®)
(100mg/4ml concentrate for solution for infusion vials)

RED
Restricted Drug Restricted

FOR ALL PRESCRIBING – Blueteq or High cost drug form required – see link from Formulary homepage. OR may be funded through the Cancer Drug Fund.


Approved in accordance with the NICE TAs below. (NB: TA 692 - NOT RECOMMENDED) 

BNF BNFc SPC
DSU June 2017: Nivolumab, pembrolizumab: reports of organ transplant rejection NICE TA357 Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab NICE TA366 Pembrolizumab for advanced melanoma not previously treated with ipilimumab NICE TA428 Pembrolizumab for treating PD-L1-positive NSC lung cancer NICE TA447 Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer NICE TA519 Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy NICE TA522 Pembrolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable NICE TA531 Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer NICE TA540: Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma (NOT RECOMMENDED; partially replaced by TA967) NICE TA553 Pembrolizumab for adjuvant treatment of resected melanoma with high risk of recurrence NICE TA557 Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer NICE TA600 Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer NICE TA661 Pembrolizumab for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma NICE TA683 Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer NICE TA692 Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy - NOT RECOMMENDED NICE TA709 Pembrolizumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency NICE TA737 Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced oesophageal and gastro-oesophageal junction cancer NICE TA766 Pembrolizumab for adjuvant treatment of completely resected stage 3 melanoma NICE TA770 Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer NICE TA772 Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma after stem cell transplant or at least 2 previous therapies NICE TA801 Pembrolizumab plus chemotherapy for untreated, triple-negative, locally recurrent unresectable or metastatic breast cancer NICE TA830 Pembrolizumab for adjuvant treatment of renal cell carcinoma NICE TA837 Pembrolizumab for adjuvant treatment of resected stage 2B or 2C melanoma NICE TA851 Pembrolizumab for neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancer NICE TA858 Lenvatinib with pembrolizumab for untreated advanced renal cell carcinoma NICE TA885 Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer (replaced by TA939) NICE TA904: Pembrolizumab with lenvatinib for previously treated advanced or recurrent endometrial cancer NICE TA914: Pembrolizumab for previously treated endometrial, biliary, colorectal, gastric or small intestine cancer with high microsatellite instability or mismatch repair deficiency NICE TA939: Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer NICE TA966: Pembrolizumab with gemcitabine and cisplatin for untreated advanced biliary tract cancer (terminated appraisal) NICE TA967: Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma in people 3 years and over NICE TA983: Pembrolizumab with trastuzumab and chemotherapy for untreated locally advanced unresectable or metastatic HER2-positive gastric or gastro-oesophageal junction adenocarcinoma - NOT RECOMMENDED NICE TA997: Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced HER2-negative gastric or gastro-oesophageal junction adenocarcinoma NICE TA1017: Pembrolizumab with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer NICE TA1037: Pembrolizumab for adjuvant treatment of resected non-small-cell lung cancer NICE TA1092: Pembrolizumab with carboplatin and paclitaxel for untreated primary advanced or recurrent endometrial cancer NICE TA1097: Enfortumab vedotin with pembrolizumab for untreated unresectable or metastatic urothelial cancer when platinum-based chemotherapy is suitable

Pertuzumab (Perjeta®)

RED
Restricted Drug Restricted

FOR ALL PRESCRIBING – Blueteq or High cost drug form required – see link from Formulary homepage.
To be prescribed by specialists in line with NICE TA's below or CDF advanced breast cancer criteria.

BNF BNFc SPC
NICE TA424: Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer NICE TA509: Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer NICE TA569: Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer

Polatuzumab vedotin 140mg (Polivy®)
(Powder for concentrate for solution for infusion)

RED
Restricted Drug Restricted

FOR ALL PRESCRIBING - Blueteq or High cost drug form required - see link from Formulary homepage.

RESTRICTED - prescribing by Consultant Oncologists only in accordance with the following NICE TA(s):-

BNF BNFc SPC BlueTeq
NICE TA649: Polatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma NICE TA874: Polatuzumab vedotin in combination for untreated diffuse large B-cell lymphoma

Ponatinib 15mg, 30mg, 45mg (Iclusig®)
(Tablets)

RED
Restricted Drug Restricted
Approved in accordance with NICE TA451 for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia.
BNF BNFc SPC
MHRA DSU Oct 2018: Ponatinib (Iclusig▼): reports of posterior reversible encephalopathy syndrome NICE TA451: Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia

Rucaparib (Rubraca®)
(200mg, 250mg and 300mg film-coated tablets)

RED
Restricted Drug Restricted

FOR ALL PRESCRIBING - Blueteq or High cost drug form required - see link from Formulary Home Page.

RESTRICTED USE - To be used only in accordance with the following NICE TA (s) - Cancer Drugs Fund

BNF BNFc SPC
MHRA DSU: Rucaparib (Rubraca▼): withdrawal of third-line treatment indication NICE TA611 Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer (replaced by TA1007) NICE TA1007: Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer NICE TA1055: Rucaparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy

Ruxolitinib (Jakavi®)

RED
Restricted Drug Restricted

FOR ALL PRESCRIBING – Blueteq or High cost drug form required – see link from Formulary homepage.
5mg, 10mg & 15mg Tablets

Approved in accordance with NICE TA386

BNF BNFc SPC
NICE TA386: Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis NICE TA921: Ruxolitinib for treating polycythaemia vera

Sacituzumab govitecan (Trodelvy®)
(180 mg powder for concentrate for solution for infusion)

RED
Restricted Drug Restricted

FOR ALL PRESCRIBING – Blueteq or High cost drug form required – see link from Formulary homepage.

Approved for use in accordance with the follwing NICE TA(s):

BNF BNFc SPC BlueTeq
NICE TA819: Sacituzumab govitecan for treating unresectable triple-negative advanced breast cancer after 2 or more therapies NICE TA1089: Sacituzumab govitecan for treating hormone receptor-positive HER2-negative metastatic breast cancer after 2 or more treatments (TERMINATED APPRAISAL)

Selinexor (Nexpovio®)
(20 mg film-coated tablets)

RED
Formulary

FOR ALL PRESCRIBING – Blueteq or High cost drug form required – see link from Formulary homepage.

Approved for use in accordance with the following NICE TA(s):

BNF BNFc SPC
NICE TA970: Selinexor with dexamethasone for treating relapsed or refractory multiple myeloma after 4 or more treatments NICE TA974: Selinexor with bortezomib and dexamethasone for previously treated multiple myeloma

Sotorasib (Lumykras®)
(120 mg film-coated tablets)

RED
Restricted Drug Restricted

FOR ALL PRESCRIBING - Blueteq or High cost drug form requested - see link on Formulary Homepage.

Approved for use, via the Cancer Drugs Fund, in accordance with the following NICE TA:

BNF BNFc SPC
NICE TA781: Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer

Talazoparib tosylate (Talzenna®)
(0.25mg, 1mg hard capsules)

RED
Restricted Drug Restricted

FOR ALL PRESCRIBING - Blueteq or high cost drug form required - see link from formulary homepage.

For use in accordance with the following NICE TA(s) only:

BNF BNFc SPC
NICE TA952: Talazoparib for treating HER2-negative advanced breast cancer with germline BRCA mutations

Tebentafusp (Kimmtrak®)
(200 micrograms/ mL concentrate for solution for infusion)

RED
Restricted Drug Restricted

FOR ALL PRESCRIBING – Blueteq or High cost drug form required – see link from Formulary homepage.

Approved for use in accordance with the following NICE TA(s):

BNF BNFc SPC
NICE TA1027: Tebentafusp for treating advanced uveal melanoma

Teclistamab (Tecvayli®)
(10mg/ml & 90mg/ml solution for injection )

RED
Restricted Drug Restricted

FOR ALL PRESCRIBING – Blueteq or High cost drug form required – see link from Formulary homepage.

Approved for use in accordance with the following NICE TA(s):

BNF BNFc SPC
NICE TA1015: Teclistamab for treating relapsed and refractory multiple myeloma after 3 or more treatments

Tisagenlecleucel (Kymriah®)
(Infusion)

RED
Restricted Drug Restricted

FOR ALL PRESCRIBING - Blueteq or high cost drug form required - see link from formulary homepage.

For use in accordance with the following NICE TA(s) only:

BNF BNFc SPC
NICE TA554: Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years (replaced by NICE TA975) NICE TA567: Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies (replaced by NICE TA933) NICE TA933: Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies (TERMINATED APPRAISAL) NICE TA975: Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 25 years and under

Tivozanib 890mcg, 1340mcg (Fotivda®)
(Capsules)

RED
Restricted Drug Restricted

FOR ALL PRESCRIBING – Blueteq or High cost drug form required – see link from Formulary homepage.

For specialist prescribing in line with NICE TA512.

BNF BNFc SPC
NICE TA512: Tivozanib for treating advanced renal cell carcinoma

Trametinib (Mekinist®)

RED
Restricted Drug Restricted

FOR ALL PRESCRIBING – Blueteq or High cost drug form required – see link from Formulary homepage.
Restricted - for Oncologists in line with the NICE TA's below.

BNF BNFc SPC
NICE TA396: Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma NICE TA544: Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma NICE TA898: Dabrafenib plus trametinib for treating BRAF V600 mutation-positive advanced non-small-cell lung cancer NICE TA977: Dabrafenib with trametinib for treating BRAF V600E mutation-positive glioma in children and young people aged 1 year and over

Trastuzumab deruxtecan (Enhertu®)
(100 mg powder for concentrate for solution for infusion)

RED
Restricted Drug Restricted

FOR ALL PRESCRIBING -Blueteq or High cost drug form required - see link from Formulary Homepage

For use in accordance with the following NICE TAs (Funding via Cancer Drugs Fund for TA 704):-

BNF BNFc SPC
NICE TA704: Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies NICE TA862: Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments NICE TA976: Trastuzumab deruxtecan for treating HER2-mutated advanced non-small-cell lung cancer after platinum-based chemotherapy (TERMINATED APPRAISAL) NICE TA992: Trastuzumab deruxtecan for treating HER2-low metastatic or unresectable breast cancer after chemotherapy (NOT RECOMMENDED) NICE TA1112: Trastuzumab deruxtecan for treating hormone receptor-positive HER2-low metastatic breast cancer after 2 or more endocrine treatments (TERMINATED APPRAISAL)

Tremelimumab (Imjudo®)
(20 mg/ml concentrate for solution for infusion)

RED
Restricted Drug Restricted

FOR ALL PRESCRIBING – Blueteq or High cost drug form required – see link from Formulary homepage.

Approved for use in accordance with the follwing NICE TAs:

BNF BNFc SPC BlueTeq
NICE TA1090: Durvalumab with tremelimumab for untreated advanced or unresectable hepatocellular carcinoma

Tretinoin 10mg
(Capsules)

RED
Restricted Drug Restricted

Restricted to prescribing by Consultant Haematologists for early treatment of suspected acute promyelocytic leukaemia (APL), a haematological emergency.

LDH: Stocked in the Emergency Drug Cupboard.

N.B. Also known as ATRA (all-trans retinoic acid) in clinical trials.

BNF BNFc SPC

Venetoclax 10mg, 50mg, 100mg (Venclyxto®)
(Tablets)

RED
Restricted Drug Restricted

FOR ALL PRESCRIBING – Blueteq or High cost drug form required – see link from Formulary homepage.
Approved in accordance with NICE TAs below.

BNF BNFc SPC
MHRA DSU Dec 2021: updated recommendations on tumour lysis syndrome (TLS) NICE TA487: Venetoclax for treating chronic lymphocytic leukaemia NICE TA561: Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia NICE TA663: Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia NICE TA765: Venetoclax with azacitidine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable NICE TA787: Venetoclax with low dose cytarabine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable NICE TA796: Venetoclax for treating chronic lymphocytic leukaemia NICE TA891: Ibrutinib with venetoclax for untreated chronic lymphocytic leukaemia

Selpercatinib (Retsevmo®)
(40mg, 80mg hard capsules)

RED
Restricted Drug Restricted

FOR ALL PRESCRIBING – Blueteq or High cost drug form required – see link from Formulary homepage.

Approved for use in accordance with the following NICE TAs (NB: TA742 and TA760 commissioned via the Cancer Drugs Fund):

BNF BNFc SPC BlueTeq
NICE TA742: Selpercatinib for treating advanced thyroid cancer with RET alterations NICE TA760: Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer NICE TA911: Selpercatinib for untreated RET fusion-positive advanced non-small-cell lung cancer NICE TA1038: Selpercatinib for advanced thyroid cancer with RET alterations after treatment with a targeted cancer drug in people 12 years and over NICE TA1039: Selpercatinib for advanced thyroid cancer with RET alterations untreated with a targeted cancer drug in people 12 years and over NICE TA1042: Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer
Non formulary items

Aflibercept (Zaltrap®)

 
Non Formulary
Not recommended by NICE for malignant indications.

BNF BNFc SPC
NICE TA307: Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy NICE TA346: Aflibercept for treating diabetic macular oedema

Olaratumab (Lartruvo®) (Intravenous infusion)

DNP
Non Formulary

Marketing authorisation and NICE TA465 withdrawn July 2019.

No new patients to be initiated and existing patients are no longer funded by NHS England.

BNF BNFc SPC
MHRA DSU June 2019: Lartruvo¥ (olaratumab): withdrawal of the EU marketing authorisation due to lack of efficacy NICE TA465: Olaratumab in combination with doxorubicin for treating advanced soft tissue sarcoma
08.01.05 Amsacrine
08.01.05 Arsenic trioxide
08.01.05 Bevacizumab
08.01.05 Bexarotene
08.01.05 Bortezomib
08.01.05 Brentuximab vedotin
08.01.05 Cetuximab
08.01.05 Crisantaspase
08.01.05 Dacarbazine and Temozolomide
08.01.05 Erlotinib
08.01.05 Hydroxycarbamide
08.01.05 Imatinab
08.01.05 Ipilimumab
08.01.05 Mitotane
08.01.05 Panitumumab
08.01.05 Pentostatin
08.01.05 Platinum compounds
08.01.05 Porfimer sodium and temoporfin
08.01.05 Procarbazine
08.01.05 Protein kinase inhibitors
08.01.05 Taxanes
08.01.05 Topoisomerase I inhibitors
08.01.05 Trabectedin
08.01.05 Trastuzumab
08.01.05 Tretinoin
08.01.05 Vismodegib
Classifications
GREEN
May be initiated in any care setting
Amber SPA
Specialist to advise therapy and provide first 28 days supply, continuation in Primary Care
Amber SPIS
Specialist to initiate and stabilise medicine prior to continuation in Primary Care
SCG
To be prescribed as per Shared Care Guidance. If no SCG in place status reverts to red.
RED
Red medicines are designated as specialist only medicines which should only be prescribed by a specialist, usually within secondary care (either due to the requirement for specialist knowledge, long-term monitoring requirements, or restrictions that mean medicine supplies are only available to hospitals).
DNP
A decision has been made either locally and/or nationally not to routinely commission this preparation. Do not prescribe.
SELF
To be purchased over the counter. May be prescribed for chronic, long term conditions or on admission to hospital if essential.